Covid-19 and weak data force pipeline revamp at Reata, but the best trials go forward — with some creative adaptions
A confluence of weak clinical results and the rising tide of problems besetting clinical trials in the age of coronavirus has scuttled a significant part of the pipeline effort at Reata Pharmaceuticals.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.